uniQure Announces Company Presentations at Upcoming May Conferences

-- Investor breakfast event and webcast at ASGCT on Friday, May 12 at 7:00 a.m. EDT --

LEXINGTON, Mass. and AMSTERDAM, the Netherlands, May 01, 2017 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced company presentations at the following conferences taking place in May:

American Society of Gene and Cell Therapy (ASGCT), May 10 - 13 2017, at the Marriott Wardman Park hotel in Washington, D.C.

Five abstracts have been accepted for presentation at the ASGCT meeting. Together with their collaborators, members of uniQure's research and development team will present data focused on progress in re-administration protocols, gene therapy delivery systems and optimized vector distribution technologies in two of uniQure's key programs, hemophilia-B and Huntington's disease.
In addition, uniQure management will host an investor and analyst breakfast meeting & webcast featuring senior leaders of its research and development team. To request attendance at the meeting, taking place at May 12, 2017 at 7:00 a.m. EDT, please RSVP to Investors@uniQure.com by May 5, 2017, as space is limited.
The live webcast can be accessed through the link displayed in the Investor section of the uniQure website at: http://uniqure.com/investors-newsroom/events-presentations.php. The webcast replay will be available for at least two weeks following the live event.

UBS Global Healthcare Conference, May 22 - 24 2017, at the Grand Hyatt New York, in New York City.

Matthew Kapusta, chief executive officer, will present on Tuesday, May 23^rd, 2017 at 3:00 p.m. EDT. The live webcast can be accessed through the link displayed in the Investor section of the uniQure website at: http://uniqure.com/investors-newsroom/events-presentations.php. The webcast replay will be available for at least two weeks following the live event.

American Biomanufacturing Summit, May 23 - 24 2017, at the Hyatt Regency Mission Bay Spa & Marina, in San Diego, California.

Lance Weed, Vice President of US Operations, will be presenting: Developing a Scalable Disposable Manufacturing Facility for Producing Gene Therapies, on May 24 at 3:00 p.m. PT. uniQure's Lexington-based facility is one of the largest, most versatile gene therapy manufacturing facilities in the world, with state-of-the-art commercial-scale production capabilities that utilize 100% single-use components.

About uniQure
uniQure is delivering on the promise of gene therapy - single treatments with potentially curative results. We are leveraging our modular and validated technology platform to rapidly advance a pipeline of proprietary and partnered gene therapies to treat patients with hemophilia, Huntington's disease and cardiovascular diseases. www.uniQure.com.

uniQure Contacts:

Maria E. Cantor  
Direct: 339-970-7536 
Mobile:  617-680-9452 
m.cantor@uniQure.com 

Tom Malone  
Direct:  339-970-7558 
Mobile:  339-223-8541 
t.malone@uniQure.com 

Eva M. Mulder
Direct: +31 20 240 6103
Mobile: +31 6 52 33 15 79
e.mulder@uniQure.com

This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: uniQure N.V. via Globenewswire

uniQure NV (NASDAQ:QURE)
Historical Stock Chart
From Jun 2024 to Jul 2024